ProJenX is a clinical-stage biotechnology company with novel, brain-penetrant targeted therapies to address debilitating brain diseases, with an initial focus on ALS.
Total raised: $15M
Investors 1
| Date | Name | Website |
| - | Medical Ex... | medexcelca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.11.2023 | Series A | $15M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 02.11.2023 | ProJenX Holds Initial Closing of $15M Series A Financing | ProJenX, Inc., a NYC-based clinical-stage biotechnology company, announced the initial closing of a ... | finsmes.co... |
| 09.09.2022 | Meet John Prufeta, General Partner of Medical Excellence Cap... | MEC invests in cell therapy, gene therapy, regenerative medicine, synthetic biology, and AI Venture... | vator.tv/n... |
| - | ProJenX | - | fastfounde... |